We are live on ! Find out more
URGN icon

UroGen Pharma
URGN

65 hedge funds and large institutions have $109M invested in UroGen Pharma in 2022 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 12 increasing their positions, 25 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

3.49% less ownership

Funds ownership: 62.75% → 59.26% (-3.5%)

12% less capital invested

Capital invested by funds: $124M → $109M (-$14.7M)

22% less funds holding

Funds holding: 83 → 65 (-18)

52% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 25

64% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 25

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $1K

Holders
65
Holders Change
-18
Holders Change %
-21.69%
% of All Funds
1.1%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
9
Increased
12
Reduced
25
Closed
25
Calls
–
Puts
$1K
Net Calls
-$1K
Net Calls Change
+$3K

Top Buyers

Rank Fund Capital Flow
1
SCM
Stonepine Capital Management
Oregon
+$5.78M
2
Millennium Management
Millennium Management
New York
+$3.15M
3
LCM
Laurion Capital Management
New York
+$2.61M
4
OM
Opaleye Management
Massachusetts
+$1.64M
5
Wells Fargo
Wells Fargo
California
+$939K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$9.34M
2
State Street
State Street
Massachusetts
-$2.83M
3
ZCA
Zeke Capital Advisors
Pennsylvania
-$1.57M
4
Geode Capital Management
Geode Capital Management
Massachusetts
-$1.11M
5
Northern Trust
Northern Trust
Illinois
-$961K
Name Holding Trade Value Shares
Change 		Change in
Stake
SIAP
51
Sterling Investment Advisors (Pennsylvania)
Pennsylvania
$16K – – –
Public Employees Retirement Association of Colorado
52
Public Employees Retirement Association of Colorado
Colorado
$11K – – –
First Manhattan
53
First Manhattan
New York
$8K – – –
Citigroup
54
Citigroup
New York
$6K -$3.34K -486 -40%
BTI
55
Blue Trust Inc
Georgia
$6K +$4.6K +670 New
Osaic Holdings
56
Osaic Holdings
Arizona
$5K +$824 +120 +24%
SPIA
57
Steward Partners Investment Advisory
New York
$4K – – –
Fidelity Investments
58
Fidelity Investments
Massachusetts
$4K +$1.68K +244 +82%
QCG
59
Quadrant Capital Group
Ohio
$2K -$1.06K -154 -43%
New York State Common Retirement Fund
60
New York State Common Retirement Fund
New York
$1K -$92K -13,400 -99%
EI
61
Ellevest Inc
New York
$1K -$2.71K -395 -78%
Carson Wealth (CWM LLC)
62
Carson Wealth (CWM LLC)
Nebraska
$1K – – –
ZCA
63
Zeke Capital Advisors
Pennsylvania
– -$1.57M -180,000 Closed
Vanguard Group
64
Vanguard Group
Pennsylvania
– -$927K -106,468 Closed
N
65
Nuveen
North Carolina
– -$854K -94,660 Closed
Bank of New York Mellon
66
Bank of New York Mellon
New York
– -$588K -67,486 Closed
Swiss National Bank
67
Swiss National Bank
Switzerland
– -$417K -47,900 Closed
Allspring Global Investments
68
Allspring Global Investments
North Carolina
– -$415K -47,728 Closed
Charles Schwab
69
Charles Schwab
California
– -$372K -42,689 Closed
California State Teachers Retirement System (CalSTRS)
70
California State Teachers Retirement System (CalSTRS)
California
– -$253K -29,100 Closed
AllianceBernstein
71
AllianceBernstein
Tennessee
– -$213K -24,500 Closed
RhumbLine Advisers
72
RhumbLine Advisers
Massachusetts
– -$202K -23,152 Closed
UBS AM
73
UBS AM
Illinois
– -$195K -22,400 Closed
State Board of Administration of Florida Retirement System
74
State Board of Administration of Florida Retirement System
Florida
– -$136K -15,641 Closed
Deutsche Bank
75
Deutsche Bank
Germany
– -$98K -11,278 Closed
1 2
3
4

URGN Hedge Fund Activity: Q2 2022 in Review

65 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q2 2022, worth a combined $109M — down 12% from $124M a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of URGN and 9 opened new positions — a net loss of 16 holders — while 25 trimmed existing stakes and 12 added.

The largest buyer was Stonepine Capital Management, adding an estimated $5.78M. The largest seller was BlackRock, cutting an estimated $9.34M.

  • 65 institutional investors held UroGen Pharma (URGN) as of Q2 2022, down from 83 in Q1 2022.
  • Funds reported $109M of UroGen Pharma stock for Q2 2022, down 12% quarter-over-quarter.
  • 9 funds opened new UroGen Pharma positions in Q2 2022 and 25 closed out, a net change of -16 holders.
  • The largest UroGen Pharma buyer in Q2 2022 was Stonepine Capital Management, an estimated $5.78M added.
  • The largest UroGen Pharma seller in Q2 2022 was BlackRock, an estimated $9.34M sold.

Based on aggregated 13F filings for Q2 2022.